About Dr Reddys Laboratories Ltd.

About Dr. Reddy’s Laboratories Ltd.
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of ‘Good Health Can’t Wait’, we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include – USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com.

We use cookies to gain insight on how you use this website and make improvements to based on your interaction with the pages. By clicking “Accept all” you agree to the use of all cookies and the corresponding data processing. If you want us to only collect cookies that are essential for you to use this website, select "Accept only Necessary". To manage the cookies you would like to consent to, click on "Preference Centre" and save your changes. You can always come back here to change your cookie preferences.
For further details please read our cookie policy